Talphera Inc
TLPH0.402USD
-0.001-0.15%
시장 운영 시간 （ET）시세는 15분 지연됩니다
6.87M시가총액
손실P/E TTM
자세한 내용은 Talphera Inc 회사
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
회사 정보
종목 코드 TLPH
회사 이름Talphera Inc
상장일Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
직원 수13
유형Ordinary Share
회계 연도 종료Feb 11
주소1850 Gateway Drive
도시SAN MATEO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94404
전화16502163500
웹사이트https://talphera.com/
종목 코드 TLPH
상장일Feb 11, 2011
CEOMr. Vincent J. (Vince) Angotti
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
66.46K
+221.21%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
42.48K
-9.61%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
+4.55%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
+14.49%
Mr. Abhinav Jain
Mr. Abhinav Jain
Independent Director
Independent Director
2.46K
-19.08%
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
수익 분석
통화: USD마지막 업데이트: Wed, Mar 5
통화: USD마지막 업데이트: Wed, Mar 5
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
사업별USD
이름
수익
비율
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
데이터 없음
사업별
지역별
사업별USD
이름
수익
비율
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Other
0.00
0.00%
주식 보유 통계
마지막 업데이트: Fri, Aug 1
마지막 업데이트: Fri, Aug 1
주주
주주 유형
주주
주주
비율
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
주주
주주
비율
Rosalind Advisors, Inc.
9.77%
Nantahala Capital Management, LLC
9.72%
Armistice Capital LLC
4.34%
Bleichroeder LP
2.08%
Angotti Vincent J
1.79%
Other
72.29%
주주 유형
주주
비율
Hedge Fund
25.46%
Investment Advisor
4.28%
Individual Investor
2.62%
Investment Advisor/Hedge Fund
1.06%
Research Firm
0.45%
Venture Capital
0.07%
Other
66.06%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
79
6.96M
33.93%
-504.17K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
2023Q3
127
7.03M
43.10%
+3.84M
2023Q2
136
1.17M
10.69%
-920.00K
2023Q1
169
1.22M
11.24%
-974.29K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Rosalind Advisors, Inc.
2.00M
9.77%
+1.39M
+226.41%
Mar 31, 2025
Nantahala Capital Management, LLC
1.99M
9.72%
--
--
Apr 25, 2025
Armistice Capital LLC
890.35K
4.34%
-661.26K
-42.62%
Dec 31, 2023
Bleichroeder LP
426.62K
2.08%
+426.62K
--
Mar 31, 2025
Angotti Vincent J
367.85K
1.79%
+265.56K
+259.62%
Apr 25, 2025
Rock Springs Capital Management LP
316.46K
1.54%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
237.53K
1.16%
-3.44K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
165.61K
0.81%
+2.40K
+1.47%
Mar 31, 2025
Values First Advisors, Inc.
97.32K
0.47%
+771.00
+0.80%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
91.55K
0.45%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
날짜
유형
비율
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
Oct 25, 2022
Merger
20<1
